The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled Trial
Open accessAbstract
BACKGROUND: Invasive pulmonary aspergillosis (IPA) is a significant problem in patients with chemotherapy-induced prolonged neutropenia. Because pulmonary deposition of conidia is the first step in developing IPA, we hypothesized that inhalation of liposomal amphotericin B would prevent IPA. METHODS: We performed a randomized, placebo-controlled trial of patients with hematologic disease with expected neutropenia for >or=10 days. Patients were randomized to receive liposomal amphotericin B or placebo inhalation twice a week, using an adaptive aerosol delivery system, until neutrophil counts increased to >300 cells/mm3. In subsequent neutropenic episodes, the assigned treatment was restarted. The primary end point was the occurrence of IPA according to European Organization for Research and the Treatment of Cancer-Mycoses Study Group definitions. Kaplan-Meier curves were compared with log-rank tests for intent-to-treat and on-treatment populations. RESULTS: A total of 271 patients were studied during 407 neutropenic episodes. According to the intent-to-treat analysis, 18 of 132 patients in the placebo group developed IPA versus 6 of 139 patients in the liposomal amphotericin B group (odds ratio, 0.26; 95% confidence interval, 0.09-0.72; P=.005). According to the on-treatment analysis, 13 of 97 patients receiving placebo versus 2 of 91 receiving liposomal amphotericin B developed IPA (odds ratio, 0.14; 95% confidence interval, 0.02-0.66; P=.007). Some adverse effects, but none serious, in the liposomal amphotericin B group were reported, most frequently coughing (16 patients vs. 1 patient; P=.002). CONCLUSION: In high-risk patients, prophylactic inhalation of liposomal amphotericin B significantly reduced the incidence of IPA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Galactomannan in Bronchoalveolar Lavage Fluid
Meersseman, W., Lagrou, K., Maertens, J., Wilmer, A., Hermans, G., Vanderschueren, S., Spriet, I., Verbeken, E., & Van Wijngaerden, E. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200704-606oc · Cited by 496
Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay
Marr, K. A., Laverdiere, M., Gugel, A., & Leisenring, W. (2005) · Clinical Infectious Diseases · doi:10.1086/429921 · Cited by 471
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B., & Corey, L. (2004) · Blood · doi:10.1182/blood-2003-08-2644 · Cited by 442
Musher, B., Fredricks, D., Leisenring, W., Balajee, S. A., Smith, C., & Marr, K. A. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.12.5517-5522.2004 · Cited by 283
Becker, M. J., Lugtenburg, E. J., Cornelissen, J. J., Van Der Schee, C., Hoogsteden, H. C., & De Marie, S. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04308.x · Cited by 217
Self-citationDrew, R. H., Dodds Ashley, E., Benjamin, D. K., Davis, R. D., Palmer, S. M., & Perfect, J. R. (2004) · Transplantation · doi:10.1097/01.tp.0000101516.08327.a9 · Cited by 198
Schwartz, S., Behre, G., Heinemann, V., Wandt, H., Schilling, E. C., Arning, M., Trittin, A., Kern, W. V., Boenisch, O., Bosse, D., et al. (1999) · PubMed · doi:10.1182/blood.v93.11.3654 · Cited by 165
Cornely, O. A., Ullmann, A. J., & Karthaus, M. (2003) · Blood · doi:10.1182/blood-2002-05-1356 · Cited by 129
Lowry, C. M., Marty, F. M., Vargas, S. O., Lee, J. T., Fiumara, K., Deykin, A., & Baden, L. R. (2007) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2007.00209.x · Cited by 82
Ruijgrok, E. J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.1.89 · Cited by 72
Self-citationRuijgrok, E. J., Fens, M. H. A. M., Bakker‐Woudenberg, I. A. J. M., et al. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.10.0007 · Cited by 43
Self-citationDyke, R. E. V., & Nikander, K. (2007) · Respiratory Care · doi:10.4187/respcare.07520184 · Cited by 30
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“Dosages of 5 mg/kg in a rabbit model of invasive pulmonary aspergillosis (IPA) result in dose-dependent improvement in a number of measures of efficacy, including lung weight, fungal density, infarct score, and galactomannan concentrations [43].”
Maertens, J., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W. J., Lass-Flörl, C., Ribaud, P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 470
Metadata
- Authors
- Rijnders, B. J., Cornelissen, J. J., Slobbe, L., Becker, M. J., Doorduijn, J. K., Hop, W. C. J., Ruijgrok, E. J., Löwenberg, B., Vulto, A., Lugtenburg, P. J., & de Marie, S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05
- Volume
- 46
- Issue
- 9
- Pages
- 1401-1408
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2160648428
- Cited by
- 284
- References
- 19
- FWCI
- 22.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.